Polivy logo

Efficacy

The POLARIX trial demonstrates POLIVY-R-CHP’s superiority over R-CHOP, now supported by extended follow-up data1,2,*

Watch experts perspectives

Specialist views covering a range of POLARIX trial topics

A Smiling grey-haired man wearing a blue button-up shirt.

Dr Hervé Tilly

University of Rouen, France

A smiling male medical professional wearing a white lab coat and a blue necktie.

Prof. Christopher Flowers

MD, Anderson Cancer Center, University of Texas

A portrait of a smiling middle-aged man in a suit and tie.

Dr Franck Morschhauser

MD, PhD Professor of Hematology,
University of Lille

A smiling blonde woman with short hair wearing a black top and a pink cardigan.

Dr Laurie H. Sehn

MD, MPH Clinical Assistant
Professor with the BC Cancer Agency and University
of British Columbia

POLIVY-R-CHP brings clinically meaningful improvement over R-CHOP1

Illustration of diverse people standing in the shape of the number 27 next to a large percent symbol.

POLIVY-R-CHP was superior vs R-CHOP: there was a 27% reduction of the risk of progression, relapse or death compared to R-CHOP1

Stratified hazard ratio 0.73; 95% CI, 0.57–0.95; p=0.021

Illustration of diverse people standing in the shape of the number 6.5 next to a percent symbol.

At 24 months, there was a 6.5% improvement in progression-free survival with POLIVY-R-CHP vs R-CHOP1

 

76.7% (95% CI, 72.7– 80.8) vs. 70.2% (95% CI, 65.8-74.6)1

PATIENT POPULATION


Long-term analysis reveals a continued benefit of POLIVY-R-CHP in PFS and an emerging trend in OS2


The extended 5-year analysis of POLARIX demonstrates the durable significant PFS benefit of POLIVY-R-CHP over R-CHOP1,2,3
 

Primary endpoint: Investigator-assessed Progression-free survival (PFS)

Graph showing progression-free survival with twenty-seven percent risk reduction for disease progression over seventy-two months.
Graph showing progression-free survival with twenty-seven percent risk reduction for disease progression over seventy-two months.
 

Investigator-assessed event-free survival (EFS†) – a key secondary endpoint – confirmed the PFS results and hence the clinical benefit demonstrated by POLIVY-R-CHP (HR = 0.75 [95% CI: 0.58, 0.96], p-value = 0.02).1 EFS showed a 25% reduction in the risk of death, progression, relapse, or other events.1,‡

Positive overall survival trend2

POLIVY-R-CHP was associated with numerically fewer deaths compared to R-CHOP after 5-year follow-up2
 

Overall survival (OS)

Overall survival graph comparing POLIVY-R-CHP and R-CHOP treatments with hazard ratios shown at different timepoints.
Overall survival graph comparing POLIVY-R-CHP and R-CHOP treatments with hazard ratios shown at different timepoints.
 
 
The 3-year overall survival analysis demonstrated an HR of 0.94 (95% CI, 0.67–1.33), which improved to 0.85 (95% CI, 0.63–1.15) at 5 years. Further follow-up will provide additional insights into these outcomes.1,2

“Out of every four patients that would potentially relapse on R-CHOP you’re now preventing one of those four patients from relapsing with the POLIVY-R-CHP combination.”

– Dr Laurie H. Sehn, MD, MPH

Clinical Assistant Professor with the BC Cancer Agency and University of British Columbia

 

Cumulative death incidence2


In a competing risk analysis for lymphoma-related versus non-lymphoma-related deaths, the cumulative incidence of lymphoma-related deaths at Year 5 was lower with POLIVY-R-CHP compared to R-CHOP2
 

Five-year probability of lymphoma- and non-lymphoma-related deaths (Expanded population)§

Data table comparing lymphoma-related and non-lymphoma-related death percentages between POLIVY-R-CHP and R-CHOP.
Data table comparing lymphoma-related and non-lymphoma-related death percentages between POLIVY-R-CHP and R-CHOP.

“What we want to do is try and cure them with front-line therapy, and we know that the stakes become a lot higher once they do relapse.”

– Dr Laurie H. Sehn

Clinical Assistant Professor with the BC Cancer Agency and University of British Columbia


 

POLIVY-R-CHP has the potential to decrease the burden of R/R disease1,2


Patients on POLIVY-R-CHP required 23% fewer subsequent lymphoma-related therapies compared to those on R-CHOP over 5 years2
 


Patients on POLIVY-R-CHP required 23% fewer subsequent lymphoma-related therapies compared to those on R-CHOP over 5 years2
 

Patients Receiving Subsequent Lymphoma Therapy throughout 5 years (ITT Population)

Bar chart showing twenty-three percent fewer subsequent therapies at five years for the POLIVY-R-CHP group.
  • Fewer patients with POLIVY-R-CHP had subsequent lines of therapies (25.5% with POLIVY-R-CHP compared to 35.3% with R-CHOP)2
  • Among those patients, fewer needed intensive high-cost and high-risk therapies such as CAR-T and SCT2
Bar charts comparing the number and percentage of subsequent therapies between two different clinical treatment groups.
A woman riding a bicycle wearing a helmet, next to two people standing and walking.

Patient Population

What type of patients can benefit from POLIVY?

read more
A woman riding a bicycle wearing a helmet, next to two people standing and walking.

*Stratified hazard ratios for 2 and 5 years were 0.73 (95% CI, 0.57–0.95; p=0.02) and 0.77 (95% CI, 0.62–0.97; p=0.02), respectively.1,2

†EFS defined as the time from randomization to the earliest occurrence of disease progression/relapse, death due to any cause, initiation of any non-protocol specified anti-lymphoma treatment, or biopsy-confirmed residual disease after treatment completion.1

‡Events of progression or relapse were assessed by the investigator. Other events are subsequent therapy for lymphoma or biopsy-confirmed residual disease after treatment.1

§Expanded population includes the addition of a China extension cohort (n=121); distribution of patient characteristics was not modified2

 

1L=first line; CAR-T=chimeric antigen receptor T-cell therapy; CCOD=clinical cut-off date; DLBCL=diffuse large B-cell lymphoma; HR=hazard ratio; NE=not able to be evaluated;
OS=overall survival; PFS=progression-free survival; POLIVY-R-CHP=polatuzumab vedotin + cyclophosphamide, doxorubicin, prednisone; R/R=relapsed or refractory; R-CHOP=rituximab + cyclophosphamide, doxorubicin, vincristine, prednisone; SCT=stem-cell therapy.

 

References:

  1. Tilly H, et al. N Engl J Med. 2022;386:351-63.
  2. Salles G, et al. Oral presentation at: 66th ASH; December 2024; San Diego, USA.
  3. Herrera A, et al. Poster presented at: 64th ASH; December 2022; New Orleans, USA.